AssureRx Health Forms Scientific Advisory Board to Support Pharmacogenomic Product Development for Neuropsychiatric Disorders
MASON, OH, January 7, 2013 – AssureRx Health, Inc. today announced the formation of a Scientific Advisory Board (SAB) to guide research and development of novel pharmacogenomic-based treatment decision support products. The SAB appointments coincide with the Company’s increasing emphasis on cutting-edge pharmacogenomic research and new clinical products that support healthcare providers in medication selection for patients with neuropsychiatric and other disorders.
“The addition of world-class pharmacology, bioinformatics, neuroscience, pharmacogenomic and clinical talent to guide our research provides us with a valuable resource as we continue to build AssureRx Health into the leading neuropsychiatric personalized medicine company,” said James S. Burns, president and CEO of AssureRx Health. “The pace of new discoveries in pharmacogenomics, both our own and others, is moving very rapidly. New genes, SNPs, multi-nucleotide polymorphisms, and gene sequencing provide us with multiple opportunities to bring novel, actionable and clinically-validated treatment decision support products to prescribers of medications for patients with neuropsychiatric disorders. We look forward to working with our advisors to exploit these exciting opportunities.” The SAB members include:
David A. Mrazek, MD, Professor of Pediatrics and Psychiatry, Mayo Clinic, Chairman
Brian D. Athey, PhD, Chair, Department of Computational Medicine and Bioinformatics, Associate Director, Michigan Institute for Clinical Health Research, University of Michigan Medical School, Vice Chairman
Tracy A. Glauser, MD, Associate Director of Clinical, Translational, Outcomes and Health Services Research, Cincinnati Children’s Research Foundation, Professor of Pediatrics and Neurology, Cincinnati Children’s Hospital Medical Center
James L. Kennedy, MD, Director, Neuroscience Research, Tanenbaum Centre for Pharmacogenetics, Centre for Addiction and Mental Health (CAMH), Professor of Psychiatry, University of Toronto
Lawrence J. Lesko, PhD, FCP, Professor of Pharmaceutics, Director, Center for Pharmacometrics and Systems Pharmacology, University of Florida College of Pharmacy
John P. Pestian, PhD, MBA, Professor, Pediatrics & Computer Science, University of Cincinnati, Director, Computational Medicine Center, Cincinnati Children’s Hospital Medical Center
Sheldon H. Preskorn, MD, PhD, Professor, Department of Psychiatry and Behavioral Science, University of Kansas School of Medicine, President & CEO, Clinical Research Institute
Wolfgang Sadee, Dr.rer.nat., Felts Mercer Professor of Medicine and Pharmacology, Chair, Department of Pharmacology, Professor of Pharmacy, Psychiatry and Medical Genetics, Director, OSU Program in Pharmacogenomics, Ohio State University School of Medicine
“The broad and world-class expertise contributed by these highly regarded clinicians and psychiatric treatment experts will help AssureRx Health develop new and increasingly innovative products for the benefit of patients with psychiatric and other CNS-related disorders”, said C. Anthony Altar, Ph.D., senior vice president and chief science officer of AssureRx Health. “Their active participation will help us with the anticipated market introduction of new products through 2013 and beyond.”
About AssureRx Health, Inc.
AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenomics dedicated to helping physicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Mayo Clinic and Cincinnati Children’s Hospital Medical Center are equity holders and technology collaborators.
GeneSight is a laboratory developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient’s unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual’s response to drug treatments, FDA approved manufacturer’s drug labels, peer-reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient’s genomic makeup, clinical experience and other factors can help a physician make personalized drug treatment choices for each patient.